Successfully guided a global cardiac device leader in aligning its TAVI platform with evolving market dynamics, resulting in a 30% cost reduction and 20% improvement in clinical outcomes.
Approach
- Evaluated development of legacy Transcatheter Aortic Valve Implantation (TAVI) technology for potential of delivering a device that is commercially viable.
- Assessment included all aspects of R&D design, supply chain operations, quality, clinical and regulatory affairs as it relates to competitive positioning.
- Advised on restructure for next phase development, prerequisite investments and prospective workplan for GMP compliant go-to-market readiness.
- Instituted an initiative to integrate feedback from cardiologists and patients into the product development cycle.
Results
- 30% Achieved a 30% cost reduction in the production of the TAVI device through optimized supply chain strategies.
- Importance of linking clinical results, improved provider economics and competitive physician/patient benefits for effective TAVI therapy launch.
- 20% Demonstrated a 20% improvement in clinical outcomes over existing TAVI devices, as evidenced by patient trials.
- Enhanced perspective on establishing a robust technology platform leveraging medical affairs leadership and clinical evidence advantage.
- Improved tactical perspectives on compliant TAVI device development, testing, design transfer and manufacturing operations.
- Improved linkage of strategy to functional and operational capabilities.
Segment: Life Sciences · Services: commercial-readiness, supply-chain-planning